Drugs / RP2
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04336241 | Oct 2019 → Oct 2026 expected | cancer | Replimune, Inc. | Active not recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07059611 | Sep 2026 → Nov 2027 expected | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Abramson Cancer Center at Penn Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06623110 | Jan 2025 → Jan 2027 expected | precancerous condition | Glenn J. Hanna | Recruiting | No outcome recorded |
| Phase 2 | NCT05733598 | Aug 2024 → Dec 2027 expected | biliary tract cancer, hepatocellular carcinoma | Replimune, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05733611 | Jun 2023 → Aug 2025 | colorectal cancer | Replimune, Inc. | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06581406 | Dec 2024 → Jan 2030 expected | uveal melanoma | Replimune, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RP2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06581406 ↗ |
| Action | Deplete | “changed to grow in and destroy cancer cells” NCT06623110 ↗ |
| Modality | Other / unclassified | “RP2 (Oncolytic virus)” NCT06581406 ↗ |
| Route | Other | “Patients will receive RP2 intratumorally every 2 weeks (Q2W) for 4 doses, then every 3 weeks (Q3W) for 4 doses combined with atezolizumab plus bevacizumab.” NCT05733598 ↗ |